TENAX THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Preferred Stock · Common Stock · Additional · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number of Shares · Amount · Number of Shares · Amount · paid-in capital · Accumulated deficit · stockholders'equity | ||||||||
| Balance at December 31, 2021 | 210 | $ | - | 15,754 | $2 | $282,738,851 | $(278,494,185) | $4,244,668 |
| Pre-funded warrants and warrants sold, net of offering costs | 7,930,653 | 7,930,653 | ||||||
| Exercise of pre-funded warrants | 12,893 | 1 | 1 | |||||
| Compensation on options issued | 365,314 | 365,314 | ||||||
| Net loss | (11,047,895) | (11,047,895) | ||||||
| Balance at December 31, 2022 | 210 | $ | - | 28,647 | $3 | $291,034,818 | $(289,542,080) | $1,492,741 |
| Public offering sale of common stock and warrants | 86,994 | 9 | 13,897,203 | 13,897,212 | ||||
| Offering costs | (282,647) | (282,647) | ||||||
| Exercise of pre-funded warrants for cash | 18,076 | 2 | 511,309 | 511,311 | ||||
| Exercise of pre-funded warrants, cashless | 3,259 | - | - | - | ||||
| Exercise of warrants, cashless | 161,131 | 16 | (16) | - | ||||
| Stock split and fractional shares issued | 174 | (687) | (687) | |||||
| Compensation on options issued | 190,850 | 190,850 | ||||||
| Net loss | (7,710,673) | (7,710,673) | ||||||
| Balance at December 31, 2023 | 210 | $ | - | 298,281 | $30 | $305,350,830 | $(297,252,753) | $8,098,107 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.